Effect of Bone Marrow-Derived Mesenchymal Stem Cells on Ischaemic-Reperfused Hearts in Adult Rats with Established Chronic Kidney Disease

Abstract

Background and Objectives Bone marrow-derived mesenchymal stem cells (BM-MSCs) are adult multipotent non-haematopoietic stem cells that have regeneration potential. The current study aimed to detect the ability of BM-MSCs to improve kidney and cardiac functions in adult rats with established chronic kidney disease. Methods Rats were divided into sham-operated control, untreated sub totally nephrectomised and treated sub totally nephrectomised groups. Body weight, kidney and cardiac tissue weights, plasma creatinine and urea levels and arterial blood pressure were measured. ECG was recorded, and an in vitro isolated heart study was performed. Results: Stem cell treatment decreased the elevated plasma creatinine and urea levels and decreased systolic, diastolic and mean arterial blood pressure values. These changes were accompanied by a decrease in glomerular hypertrophy with apparent normal renal parenchyma. Additionally, BM-MSCs shortened Q-To and Q-Tc intervals, all time to peak tension values, the half relaxation value at 30 min of reperfusion and the contraction time at 15 and 30 min of reperfusion. Moreover, stem cell treatment significantly increased the heart rate, QRS voltage, the peak tension at the 15- and 30-min reperfusion time points and the peak tension per left ventricle at the 30-min reperfusion time point compared to the pre-ischaemia baseline. BM-MSCs resolve inter muscular oedema and lead to the re-appearance of normal cardiomyocytes. This improvement occurs with the observations of BM-MSCs in renal and heart tissues. Conclusions BM-MSCs can attenuate chronic kidney disease progression and the associated cardiac electrophysiological and inotropic dysfunction.

Impact of Remdesivir on the kidney and potential protective capacity of Granulocyte-Colony Stimulating Factor versus Bone Marrow Mesenchymal Stem Cells in adult male albino rats

“…Group Ib: (BMSCs treated group): Each rat of this group received 0.5 ml of PKH26 labelled MSC suspension in BPS (3x10⁶ cells/ml) for two consecutive days via the tail vein [29] .…”

“…Group III (Remedesivir and BMSCs treated group) (n=13 rats): 1 ml of PKH26-labelled MSC suspension in BPS was administered to rats on day 1 following administration of remediesivir for two consecutive days (3x10⁶ cells/ml) IV via tail vein [29] .…”

Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model

“…The ability of stem cells to restore normal kidney function can be explained by their ability to undergo selective migration into damaged tissues and their ability to express growth factor receptors and chemokines released from organs with inflammatory change ( 7 ). In damaged organs, stem cells have the potential to differentiate into various tissues, such as tubular epithelial cells, mesangial cells of nephrons, podocytes, or glomerular endothelial cells ( 8 ).…”

Optimizing growth media for <italic>in vitro</italic> expansion of human bone marrow-derived mesenchymal stem cells

“…1,6 Besides human MSCs, MSCs have been isolated from different species including mice, rats, rabbits, sheep, pigs, and dogs. [7][8][9][10][11][12] Mesenchymal stem cells (MSCs) are considered of the most promising cells for gene therapy and tissue engineering. [13][14][15][16][17] MSC therapy is poised to establish a new clinical paradigm; although MSCs are originally considered to treat connective tissue defects, preclinical studies 1 revealed potent immunomodulatory properties that prompted the use of MSCs to treat numerous inflammatory conditions.…”